Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E "SECURE"


Phase N/A Results


86 patients were eliminated from the trial during the initial run-in period, leaving 732 participants. Ramipril 10 mg/day significantly reduced carotid atherosclerotic progression (Placebo mean IMT slope: 0.0217 mm/year, Ramipril 10 mg mean IMT slope: 0.018; P = 0.028). Ramipril 2.5 mg/day had no statistical effect on atherosclerotic progression (P = 0.33). Administration of vitamin E 400 IU/day also had no impact on atherosclerotic progression.